Related Experiment Videos
Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients
1Servizio di Neurologia, Istituto Nazionale Regina Elena per lo studio e la cura dei Tumori, Roma, Italy.
Abstract:
Paclitaxel is the prototype of a new class of chemotherapeutic agents with an antimitotic effect that is related to its ability to interfere with the microtubule system. It causes peripheral neurological toxicity by means of its activity on the axonal microtubules. To define the clinical and neurophysiological characteristics of paclitaxel neuropathy 23 patients undergoing paclitaxel therapy at a dose of 175 mg/m2 were studied. The patients were divided into two groups, with only one group receiving pretreatment with potentially neurotoxic drugs such as cisplatin and carboplatin. The results showed a high incidence of mild neurotoxicity in both groups. Treatment was discontinued due to severe neurotoxicity in only one patient pretreated with platinum-compounds. The clinical and neurophysiological data make it possible to define paclitaxel neurotoxicity as a distal axonal neuropathy with a summatory effect in patients pretreated with cisplatin; the possible reversibility of paclitaxel neurotoxicity requires further confirmation.
Insights
Paclitaxel chemotherapy can cause peripheral neuropathy, affecting nerve function. Pretreatment with platinum drugs may worsen this neurotoxicity, indicating a cumulative effect.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Paclitaxel is a novel chemotherapeutic agent targeting the microtubule system.
- Paclitaxel induces peripheral neurological toxicity via axonal microtubule interaction.
Purpose of the Study:
- To characterize the clinical and neurophysiological aspects of paclitaxel-induced neuropathy.
- To assess the impact of platinum-based drug pretreatment on paclitaxel neurotoxicity.
Main Methods:
- Studied 23 patients receiving paclitaxel at 175 mg/m2.
- Divided patients into two groups: one with platinum-compound pretreatment, one without.
- Evaluated clinical symptoms and neurophysiological data.
Main Results:
- High incidence of mild neurotoxicity observed in both groups.
- Severe neurotoxicity leading to treatment discontinuation occurred in one patient pretreated with platinum compounds.
- Paclitaxel neurotoxicity presents as distal axonal neuropathy, potentially with a cumulative effect when combined with cisplatin.
Conclusions:
- Paclitaxel causes distal axonal neuropathy.
- Pretreatment with platinum-based drugs may exacerbate paclitaxel neurotoxicity.
- Further studies are needed to confirm the reversibility of paclitaxel-induced neurotoxicity.